Updated:
Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd develops radiopharmaceuticals for cancer diagnosis and therapy, with a pipeline targeting PD-L1, HER2, and PSMA.
Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd is a clinical-stage biotechnology company specializing in radiopharmaceuticals for oncology. Founded to advance theranostic approaches, the firm develops agents that can both image and treat tumors using targeted radiation. The company is publicly traded on the Australian Securities Exchange (ASX: RAD). Its pipeline includes programs targeting clinically validated biomarkers such as PD-L1 (RAD-301), HER2 (RAD-201), and PSMA (RAD-101). The firm employs both small-molecule and antibody-based delivery platforms. Radiopharm Theranostics collaborates with academic and clinical research institutions for early-stage development and has not disclosed specific partnership or licensing revenue. As a publicly listed entity, Radiopharm Theranostics does not operate as a single family office or private capital vehicle. The company reports its financials through ASX filings, with funding from equity offerings and institutional investors. No assets under management, team size, or geographic footprint beyond Australia-based headquarters have been disclosed in public record. The firm's structural differentiator is its focus on theranostic pairs — a modality that links diagnostic imaging directly to therapeutic delivery — rather than broader radiopharmaceutical or oncology platforms. This specialization creates a distinct regulatory and development pathway but also narrows its addressable market relative to diversified biotech firms.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Radiopharm Theranostics Ltd's primary business focus?
Radiopharm Theranostics Ltd is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for oncology. Its core approach is theranostics — combining diagnostic imaging agents with targeted radiation therapies — to identify and treat cancer cells. The company's pipeline includes programs targeting PD-L1, HER2, and PSMA.
Is Radiopharm Theranostics Ltd publicly traded or privately held?
Radiopharm Theranostics Ltd is a publicly traded company listed on the Australian Securities Exchange under the ticker RAD. It is not a family office, private capital vehicle, or asset manager. Its financial disclosures and corporate governance are subject to ASX listing rules.
What investment stages does Radiopharm Theranostics Ltd's development programs target?
The company's pipeline programs are at various clinical and preclinical stages. Specific stage details for each candidate have not been disclosed in public filings. As a publicly listed entity, Radiopharm Theranostics reports its clinical milestones through ASX announcements.
Does Radiopharm Theranostics Ltd manage external capital or operate as an investment firm?
No. Radiopharm Theranostics Ltd is an operating biotechnology company developing radiopharmaceuticals. It does not manage third-party capital or function as an asset manager, family office, or investment fund. Its funding comes from public equity markets and institutional investors.
Where is Radiopharm Theranostics Ltd headquartered?
The company's headquarters location has not been disclosed in available public filings or its official communications. Its stock is listed on the Australian Securities Exchange, suggesting Australia-based operations, but no specific city or address has been published.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: